Curated News
By: NewsRamp Editorial Staff
October 28, 2025

Cybin Raises $175M in Direct Offering for Mental Health Breakthroughs

participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Cybin's $175M funding round with prominent investors provides capital advantage to accelerate development of breakthrough mental health treatments ahead of competitors.
  • Cybin issued 22.3M shares at $6.51 each with attached warrants exercisable at $8.14, structured to fund Phase 3 trials for CYB003 in major depressive disorder.
  • Cybin's funding advances novel mental health treatments that could provide effective, durable relief for millions suffering from depression and anxiety disorders worldwide.
  • Cybin is developing deuterated psychedelic compounds like CYB003, a modified psilocin analog with FDA Breakthrough Therapy status for treating major depressive disorder.

Impact - Why it Matters

This development represents a major vote of confidence in psychedelic medicine's potential to transform mental healthcare. With mental health disorders affecting hundreds of millions globally and traditional treatments often providing inadequate relief, Cybin's novel approaches could offer breakthrough solutions for conditions like major depressive disorder and anxiety. The substantial investment from reputable institutional backers validates the growing acceptance of psychedelic-assisted therapies in mainstream medicine. For patients struggling with treatment-resistant mental health conditions, this funding accelerates the development of potentially life-changing treatments that could provide lasting relief where current options have failed. The progress also signals a broader shift in how mental health is treated, moving beyond conventional pharmaceuticals toward more targeted, neuroplasticity-enhancing therapies.

Summary

Cybin Inc., a late-stage breakthrough neuropsychiatry company, has announced a significant registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants at US$6.51 per share, generating aggregate gross proceeds of US$175,009,911.45. This substantial capital raise attracted participation from both new and existing institutional investors including prominent names such as Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group. Each share or pre-funded warrant comes with 0.35 of one common share purchase warrant exercisable at US$8.14 per share, with specific conditions tied to the company's clinical trial progress and stock performance.

The company, which operates across Canada, the United States, the United Kingdom and Ireland, is focused on revolutionizing mental healthcare through novel psychedelic-based treatments. Cybin's current development pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder, along with a research pipeline of investigational 5-HT-receptor focused compounds. The company's mission centers on addressing the large unmet need in mental health treatment by developing next-generation therapies that provide effective and durable results for patients suffering from various mental health conditions.

This news was disseminated through the InvestorBrandNetwork's Dynamic Brand Portfolio, which provides specialized communications services including advanced wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release optimization, social media distribution to millions of followers, and comprehensive corporate communications solutions. The full details of this significant financing round and Cybin's ongoing clinical developments can be accessed through the company's official newsroom and the provided InvestorWire links, offering investors and stakeholders comprehensive information about this important milestone in the neuropsychiatry sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cybin Raises $175M in Direct Offering for Mental Health Breakthroughs

blockchain registration record for this content.